Keyword search (4,164 papers available)

"Leyton M" Authored Publications:

Title Authors PubMed ID
1 Decriminalization or more treatment? Comparing 2 approaches to the drug overdose crisis Caswell C; Krausz RM; Leyton M; 40541419
CSBN
2 A multimodal neuroimaging study of youth at risk for substance use disorders: Functional magnetic resonance imaging and [18F]fallypride positron emission tomography Nikolic M; Cox SML; Jaworska N; Castellanos-Ryan N; Dagher A; Vitaro F; Brendgen M; Parent S; Boivin M; Côté S; Tremblay RE; Séguin JR; Leyton M; 39725679
CSBN
3 Ending the overdose epidemic by ending the war on drug users: Can this work? Leyton M; Krausz RM; 38383036
CSBN
4 Mesocorticolimbic function in cocaine polydrug users: A multimodal study of drug cue reactivity and cognitive regulation Scala SG; Kang MS; Cox SML; Rosa-Neto P; Massarweh G; Leyton M; 38221806
CSBN
5 Learning from opioid withdrawal: Effects on striatal dopamine (Commentary on Ahn et al., 2023) Leyton M; Nikolic M; 38129315
CSBN
6 Brain PET Imaging in Small Animals: Tracer Formulation, Data Acquisition, Image Reconstruction, and Data Analysis Bdair H; Kang MS; Ottoy J; Aliaga A; Kunach P; Singleton TA; Blinder S; Soucy JP; Leyton M; Rosa-Neto P; Kostikov A; 38006502
PERFORM
7 Cocaine cue-induced mesocorticolimbic activation in cocaine users: Effects of personality traits, lifetime drug use, and acute stimulant ingestion D' Amour-Horvat V; Cox SML; Dagher A; Kolivakis T; Jaworska N; Leyton M; 34463411
CSBN
8 Why did the kitten cross the road? A meditation on positive versus negative reinforcement in addiction. Leyton M 33497168
CSBN
9 Metabotropic glutamate type 5 receptor binding availability during dextroamphetamine sensitization in mice and humans. Smart K, Nagano-Saito A, Milella MS, Sakae DY, Favier M, Vigneault E, Louie L, Hamilton A, Ferguson SSG, Rosa-Neto P, Narayanan S, El Mestikawy S, Leyton M, Benkelfat C 32559027
CSBN
10 mGlu5 receptor availability in youth at risk for addictions: effects of vulnerability traits and cannabis use. Cox SML, Tippler M, Jaworska N, Smart K, Castellanos-Ryan N, Durand F, Allard D, Benkelfat C, Parent S, Dagher A, Vitaro F, Boivin M, Pihl RO, Côté S, Tremblay RE, Séguin JR, Leyton M 32413893
CSBN
11 Extra-striatal D2/3 receptor availability in youth at risk for addiction. Jaworska N, Cox SML, Tippler M, Castellanos-Ryan N, Benkelfat C, Parent S, Dagher A, Vitaro F, Boivin M, Pihl RO, Côté SM, Tremblay RE, Séguin JR, Leyton M 32259831
CSBN
12 Cannabis legalization: Did we make a mistake? Update 2019 Leyton M 31452361
PSYCHOLOGY
13 Legalizing marijuana. Leyton M 26898727
CSBN
14 Cocaine cue-induced dopamine release in the human prefrontal cortex. Milella MS, Fotros A, Gravel P, Casey KF, Larcher K, Verhaeghe JA, Cox SM, Reader AJ, Dagher A, Benkelfat C, Leyton M 26900792
CSBN
15 Dopamine and light: effects on facial emotion recognition. Cawley E, Tippler M, Coupland NJ, Benkelfat C, Boivin DB, Aan Het Rot M, Leyton M 28633582
CSBN
16 Are people with psychiatric disorders violent? Leyton M 29688170
CSBN
17 Are people with psychiatric disorders violent? Leyton M 29947604
CSBN
18 Neuroimaging tests for clinical psychiatry: Are we there yet? Leyton M, Kennedy SH 28639935
IMAGING
19 Dopamine cross-sensitization between psychostimulant drugs and stress in healthy male volunteers. Booij L, Welfeld K, Leyton M, Dagher A, Boileau I, Sibon I, Baker GB, Diksic M, Soucy JP, Pruessner JC, Cawley-Fiset E, Casey KF, Benkelfat C 26905412
PSYCHOLOGY
20 Effect of (Z)-isomer content on [11C]ABP688 binding potential in humans. Smart K, Cox SML, Kostikov A, Shalai A, Scala SG, Tippler M, Jaworska N, Boivin M, Séguin JR, Benkelfat C, Leyton M 30607444
CSBN
21 Sex differences in [11C]ABP688 binding: a positron emission tomography study of mGlu5 receptors. Smart K, Cox SML, Scala SG, Tippler M, Jaworska N, Boivin M, Séguin JR, Benkelfat C, Leyton M 30627817
CSBN
22 Posterior dopamine D2/3 receptors and brain network functional connectivity. Nagano-Saito A, Lissemore JI, Gravel P, Leyton M, Carbonell F, Benkelfat C 28700819
PERFORM

 

Title:Brain PET Imaging in Small Animals: Tracer Formulation, Data Acquisition, Image Reconstruction, and Data Analysis
Authors:Bdair H,  Kang MS,  Ottoy J,  Aliaga A,  Kunach P,  Singleton TA,  Blinder S,  Soucy JP,  Leyton M,  Rosa-Neto P,  Kostikov A
Link:https://pubmed.ncbi.nlm.nih.gov/38006502/
DOI:10.1007/978-1-0716-3499-8_16
Publication:Methods in molecular biology (Clifton, N.J.)
Keywords:PET image acquisition;  PET image analysis;  PET image reconstruction;  PET tracers;  Positron emission tomography;  Preclinical imaging; 
PMID:38006502 Category: Date Added:2023-11-26
Dept Affiliation: PERFORM
1 Department of Neurology and Neurosurgery, McGill University, Montreal, QC, Canada.
2 Department of Psychiatry, McGill University, Montreal, QC, Canada.
3 McConnell Brain Imaging Centre, Montreal Neurological Institute-Hospital (The Neuro), McGill University, Montreal, QC, Canada.
4 Translational Neuroimaging Laboratory, Research Centre for Studies in Aging, Douglas Research Institute, McGill University, Montreal, QC, Canada.
5 LC Campbell Cognitive Neurology Unit, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada.
6 PERFORM Centre, Concordia University, Montreal, QC, Canada.
7 Department of Psychology, McGill University, Montreal, QC, Canada.
8 Center for Studies in Behavioral Neurobiology, Concordia University, Montreal, QC, Canada.
9 Department of Neurology and Neurosurgery, McGill University, Montreal, QC, Canada. alexey.kostikov@mcgill.ca.
10 Translational Neuroimaging Laboratory, Research Centre for Studies in Aging, Douglas Research Institute, McGill University, Montreal, QC, Canada. alexey.kostikov@mcgill.ca.
11 McConnell Brain Imaging Centre, Montreal Neurological Institute-Hospital (The Neuro), McGill University, Montreal, QC, Canada. alexey.kostikov@mcgill.ca.
12 Department of Chemistry, McGill University, Montreal, QC, Canada. alexey.kostikov@mcgill.ca.

Description:

Positron emission tomography (PET) is a noninvasive functional imaging modality that involves in vivo detection of spatiotemporal changes in the binding of radioactive pharmaceuticals (a.k.a. PET tracers) to their target sites in different organs. The development of new PET tracers commonly involves their preclinical evaluation in small rodents. Moreover, laboratory animal PET research is now being used with progressively greater frequency to complement human PET studies, to investigate in greater depth the underlying pathophysiology of human diseases, and to monitor the efficiency of novel therapeutic interventions. Here we describe the steps toward a successful small animal PET study, from tracer formulation and image acquisition to data reconstruction and analysis of the acquired scans, with a particular focus on its utility for the brain.





BookR developed by Sriram Narayanan
for the Concordia University School of Health
Copyright © 2011-2026
Cookie settings
Concordia University